Atrasentan: Targeting the endothelin axis in prostate cancer

Expert Opinion on Investigational Drugs

Volumn 13, Issue 12, 2004, Pages 1631-1640

  Jimeno, Antonio ^b   Carducci, Michael ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

Atrasentant; Endothelin I; Endothelin receptor A; Prostate cancer

Indexed keywords

ANGIOTENSIN; ATRASENTAN; ATRIAL NATRIURETIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; BIOCHEMICAL MARKER; BRADYKININ; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P450 3A5; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NITRIC OXIDE; NORADRENALIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN; SOMATOMEDIN; THROMBIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; UROKINASE; VASCULOTROPIN; VASOPRESSIN;

ANGIOGENESIS; ARTICLE; ASTHENIA; BONE DEVELOPMENT; BONE DISEASE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL DEATH; CHEMICAL STRUCTURE; CLINICAL TRIAL; DISEASE COURSE; DRUG TARGETING; DYSPNEA; FOOD DRUG INTERACTION; HEADACHE; HEART FAILURE; HEMODILUTION; HUMAN; HYPONATREMIA; HYPOTENSION; INFECTION; MALE; NAUSEA; NOCICEPTIVE STIMULATION; PERIPHERAL EDEMA; PROSTATE CANCER; PROTEIN EXPRESSION; RASH; RECEPTOR DOWN REGULATION; RHINITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT GAIN; XEROSTOMIA;

CARCINOMA; CLINICAL TRIALS, PHASE III; ENDOTHELIN-1; HUMANS; MALE; PROSTATIC NEOPLASMS; PYRROLIDINES; RECEPTOR, ENDOTHELIN A;

EID: 10344233659     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.12.1631     Document Type: Article

References (58)

1. GRONBERG H: Prostate cancer epidemiology. Lancet (2003) 361:859-864.
2. TANNOCK IF, DE WIT R, BERRY WR et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. (2004) 351:1502-1512.
3. PETRYLAK DP, TANGEN CM, HUSSAIN MH et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. (2004) 351 1513-1520.
4. FOX E, CURT GA, BALIS FM: Clinical trial design for target-based therapy. Oncologist (2002) 7:401-409.
5. RUBIN SA, LEVIN ER: Clinical review 53: the endocrinology of vasoactive peptides: synthesis to function. J. Clin. Endocrinol. Metab. (1994) 78:6-10.
6. BREMNES T, PAASCHE JD, MEHLUM A, SANDBERG C, BREMNES B, ATTRAMADAL H: Regulation and intracellular trafficking pathways of the endothelin receptors. J. Biol. Chem. (2000) 275:17596-17604.
7. LEVIN ER: Endothelins. N. Engl. J. Med. (1995) 333 356-363.
8. GRAY GA, WEBB DJ: The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol. Ther. (1996) 72:109-148.
9. BAGNATO A, NATALI PG: Endothelin receptors as novel targets in tumor therapy. J. Transl. Med. (2004) 2:16.
10. OBARA K, KOIDE M, ISHIKAWA T, TANABE Y, NAKAYAMA K: Protein kinase Cδ but not PKCE activity is involved in contractile potentiation by endothelin-1 in the porcine coronary artery. J. Cardiovasc. Pharmacol. (2000) 36:S120-S121.
11. DAUB H, WEISS FU, WALLASCH C, ULLRICH A: Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature (1996) 379:557-560.
12. JIANG ZY, ZHOU QL, CHATTERJEE A et al.: Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. Diabetes (1999) 48 1120-1130.
13. BATTISTINI B, CHAILLER P, D'ORLEANS-JUSTE P, BRIERE N, SIROIS P: Growth regulatory properties of endothelins. Peptides (1993) 14:385-399.
14. VACCA F, BAGNATO A, CATT KJ, TECCE R: Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res. (2000) 60:5310-5317.
15. CLARKE JG, BENJAMIN N, LARKIN SW, WEBB DJ, DAVIES GJ, MASERI A: Endothelin is a potent long-lasting vasoconstrictor in men. Am. J. Physiol. (1989) 257:H2033-H2035.
16. REMUZZI G, PERICO N, BENIGNI A: New therapeutics that antagonize endothelin: promises and frustrations. Nat. Rev. Drug Discov. (2002) 1:986-1001.
17. TOUYZ RM, SCHIFFRIN EL: Role of endothelin in human hypertension. Can. J. Physiol. Pharmacol. (2003) 81:533-541.
18. NELSON J, BAGNATO A, BATTISTINI B, NISEN P: The endothelin axis: emerging role in cancer. Nat. Rev. Cancer (2003) 3 110-116.
19. NELSON JB, HEDICAN SP, GEORGE DJ et al.: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. (1995) 1:944-949.
20. NELSON JB, CHAN-TACK K, HEDICAN SP et al.: Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. (1996) 56:663-668.
21. PAPANDREOU CN, USMANI B, GENG Y et al.: Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat. Med. (1998) 4 50-57.
22. NELSON JB, LEE WH, NGUYEN SH et al.: Methylation of the 5′CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res. (1997) 57:35-37.
23. USMANI BA, HARDEN B, MAITLAND NJ, TURNER AJ: Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines. Clin. Sci. (2002) 103(Suppl. 48):314S-317S.
24. SALANI D, DI CASTRO V, NICOTRA MR et al.: Role of endothelin-1 in neovascularization of ovarian carcinoma. Am. J. Pathol. (2000) 157:1537-1547.
25. KOPETZ ES, NELSON JB, CARDUCCI MA: Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest. New Drugs (2002) 20:173-182.
26. EBERL LP, VALDENAIRE O, SAINTGIORGIO V, JEANNIN JF, JUILLERAT-JEANNERET L: Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells. Int. J. Cancer (2000) 86:182-187.
27. DEL BUFALO D, DI CASTRO V, BIROCCIO A et al.: Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol. Pharmacol. (2002) 61:524-532.
28. DEL BUFALO D, DI CASTRO V, BIROCCIO A et al.: Endothelin-1 acts as a survival factor in ovarian carcinoma cells. Clin. Sci. (2002) 103(Suppl. 48):302S-305S.
29. ROSANO L, VARMI M, SALANI D et al.: Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res. (2001) 61:8340-8346.
30. ROSANO L, SALANI D, DI CASTRO V, SPINELLA F, NATALI PG, BAGNATO A: Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin. Sci. (2002) 103(Suppl. 48):306S-309S.
31. ROSANO L, SPINELLA F, DI CASTRO V et al.: Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo. Am. J. Pathol. (2003) 163 753-762.
32. BAGNATO A, ROSANO L, SPINELLA F, DI CASTRO V, TECCE R, NATALI PG: Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res. (2004) 64:1436-1443.
33. SPINELLA F, ROSANO L, DI CASTRO V, NICOTRA MR, NATALI PG, BAGNATO A: Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells. J. Biol. Chem. (2003) 278:41294-41301.
34. SALANI D, TARABOLETTI G, ROSANO L et al.: Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am. J. Pathol. (2000) 157 1703-1711.
35. SPINELLA F, ROSANO L, DI CASTRO V, NATALI PG, BAGNATO A: Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1α in ovarian carcinoma cells. J. Biol. Chem. (2002) 277:27850-27855.
36. SPINELLA F, ROSANO L, DI CASTRO V, NICOTRA MR, NATALI PG, BAGNATO A: Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells. Clin. Cancer Res. (2004) 10:4670-4679.
37. GUPTA S, SRIVASTAVA M, AHMAD N, BOSTWICK DG, MUKHTAR H: Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate (2000) 42:73-78.
38. PRUTHI RS, DERKSEN JE, MOORE D: A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int. (2004) 93:275-278.
39. NELSON JB, NGUYEN SH, WU-WONG JR et al.: New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology (1999) 53:1063-1069.
40. CHIAO JW, MOONGA BS, YANG YM et al.: Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br. J. Cancer (2000) 83 360-365.
41. YIN JJ, MOHAMMAD KS, KAKONEN SM et al.: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. USA (2003) 100:10954-10959.
42. GUISE TA, YIN JJ, MOHAMMAD KS: Role of endothelin-1 in osteoblastic bone metastases. Cancer (2003) 97:779-784.
43. POMONIS JD, ROGERS SD, PETERS CM, GHILARDI JR, MANTYH PW: Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception. J. Neurosci. (2001) 21:999-1006.
44. JARVIS MF, WESSALE JL, ZHU CZ et al.: ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain. Eur. J. Pharmacol. (2000) 388:29-35.
45. YUYAMA H, KOAKUTSU A, FUJIYASU N et al.: Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain. Eur. J. Pharmacol. (2004) 492 177-182.
46. KHODOROVA A, NAVARRO B, JOUAVILLE LS et al.: Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. Nat. Med. (2003) 9:1055-1061.
47. WU-WONG JR, DIXON DB, CHIOU WJ et al.: Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies. Clin. Sci. (2002) 103(Suppl. 48):107S-111S.
48. ZHU T, ANDRE A, FACEY I et al.: Effect of ketoconazole (KET) on the pharmacokinetics (PK) of atrasentan (ABT-627, ATN). Proceedings of the 40th American Society of Clinical Oncology annual meeting. New Orleans, LA, USA (2004) Abstract 4727.
49. XIONG H, JANKOWSKI J, ASHBRENNER E et al.: Effect of rifampin (RIF) on the pharmacokinetics (PK) of atrasentan (ABT-627, ATN). Proceedings of the 40th American Society of Clinical Oncology annual meeting. New Orleans, LA, USA (2004) Abstract 4728.
50. KLEIN CE, SCHROEDER MC, FACEY I et al.: Effect of atrasentan (ABT-627, ATN) on the pharmacokinetics (PK) of fexofenadine (FEX). Proceedings of the 40th American Society of Clinical Oncology annual meeting. New Orleans, LA, USA (2004) Abstract 4723.
51. KATZ DA, GRIMM DR, CARR R et al.: Pharmacogenetic meta-analysis suggests that atrasentan is an organic anion transport protein C substrate. Clin. Pharm. Ther. (2004) (2004) 75:94.
52. SAMARA E, DUTTA S, CAO G, GRANNEMAN GR, DORDAL MS, PADLEY RJ: Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist. J. Clin. Pharmacol. (2001) 41:397-403.
53. CARDUCCI MA, NELSON JB, BOWLING MK et al.: Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J. Clin. Oncol. (2002) 20:2171-2180.
54. ZONNENBERG BA, GROENEWEGEN G, JANUS TJ et al.: Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin. Cancer Res. (2003) 9:2965-2972.
55. RYAN CW, VOGELZANG NJ, VOKES EE et al.: Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin. Cancer Res. (2004) 10 4406-4411.
56. CARDUCCI MA, PARLEY RJ, BREUL J et al.: Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, Phase II, placebo-controlled trial. J. Clin. Oncol. (2003) 21:679-689.
57. NELSON JB, NABULSI AA, VOGELZANG NJ et al.: Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J. Urol. (2003) 169:1143-1149.
58. CARDUCCI MA, NELSON JB, SAAD F et al.: Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: Phase III study. Proceedings of the 40th American Society of Clinical Oncology annual meeting. New Orleans, LA, USA (2004) Abstract 4508.